Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

Drug therapy for acute lymphoblastic leukemia in children


Treatment of ALL is principally chemotherapy to reduce, and in most cases, eliminate the leukemic clone.

This treatment, unfortunately, also causes intense side effects on normal hematopoiesis. After chemotherapy treatments, for periods of one to multiple weeks, the child will have bone marrow aplasia with varying degrees of neutropenia, thrombocytopenia and anemia. The child is therefore susceptible to potentially serious infections and/or bleeding.  

Norway follows the NOPHO ALL 2008 protocol (Nordic Society for Pediatric Hematology and Oncology). Patients are separated into 3 intensity groups:

  • Standard risk
  • Intermediate risk
  • High risk

In principle, the treatment has the same staging in all risk groups:

  • Consolidation
  • Maintenance


  • Acute lymphoblastic leukemia


  • Control the disease on a hematological, cytogenetic, and molecular level
  • Cure

Oslo University Hospital shall not be liable for any loss whether direct, indirect, incidental or consequential, arising out of access to, use of, or reliance upon any of the content on this website. Oslo University Hospital© 2017